|Bid||15.150 x 900|
|Ask||15.400 x 1800|
|Day's Range||14.450 - 15.510|
|52 Week Range||13.700 - 21.250|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
President and CEO of Arvinas Inc (NASDAQ:ARVN) John G Houston bought 30,000 shares of ARVN on 10/01/2018 at an average price of $16 a share.
Shares of Arvinas Inc. soared in their public debut on the Nasdaq exchange, after the biopharmaceutical company's upsized initial public offering priced at the top of the expected range. The first trade was at $21 at 10:36 a.m. ET for 466,365 shares, or 31% above the $16 IPO price. The stock has pared some gains since to trade up 25%. The company had said earlier this month it planned to offer 6.7 million shares in the IPO, but raised it late-Wednesday to 7.5 million. The IPO pricing was at the top of the expected range of $14 to $16, as the company raised $120 million. The company could raise up to $138 million if the underwriters exercise all of the options granted to purchase additional shares. With 32.16 million shares outstanding after the offering, the IPO price values the company at about $514.5 million. The company has gone public at a time that the Renaissance IPO ETF has gained 3.4% over the past three months and the S&P 500 has tacked on 8.2%.
Biotechnology startup Arvinas Inc. late Wednesday priced an upsized initial public offering of 7.5 million shares at $16 apiece, the high end of the expected price range.
NEW HAVEN, Conn., Sept. 26, 2018-- Arvinas, Inc., a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...